A meta-analysis of real-world lecanemab use found amyloid-related imaging abnormalities (ARIA) occurred in 15.1% of cases, with higher risk in APOE ε4 homozygotes and in people with baseline microhemorrhages. The analysis also reported limited cognitive efficacy evidence relative to controlled trials, emphasizing the gap between routine use and trial-grade outcomes. In parallel, pharmacovigilance work continued to refine signal attribution by narrowing jaw osteonecrosis triggers to glucocorticoids and asparaginase after checks for misclassification and confounding. The combined picture highlights how post-marketing surveillance is increasingly used to improve risk characterizations and guide monitoring protocols. For clinicians and developers, both results reinforce the need for population- and baseline-feature-aware safety planning alongside efficacy claims.